CRYPTOLOGY-ASSET-GROUP
Cryptology Asset Group (ISIN: MT0001770107; Ticker: CAP:GR), a leading European investment company for blockchain- and crypto-related businesses founded by Christian Angermayer and Mike Novogratz, intends to invest USD 100 million over the next 24 months into crypto-related venture funds.
Cryptology will take an entrepreneurial approach in building its fund portfolio and will focus on first time funds and emerging managers, globally, including seeding funds and taking stakes in GPs as well.
Christian Angermayer, Founder of Cryptology, explains: "We are at the very beginning of the crypto revolution, and we strive to become one of the leading global investors in this very nascent asset class. Our fund investment strategy will focus on emerging talent, taking a global approach, and will encompass both funds investing in equity stakes of crypto- and blockchain related companies as well as funds investing in crypto assets and tokens."
Patrick Lowry, CEO of Cryptology, adds: "There is no better asset class to bet on than crypto, in my opinion. Within just three years, Cryptology has grown invested capital of approx. EUR 27 million into an NAV of approx. EUR 450 million, as of June 1, 2021. This results in an estimated IRR of more than 300% per year, which is an impressive testimony to the tectonic shift we are seeing in front of our very eyes. We will work hard to continue this success story in the coming years and decades.
Patrick further elaborates: "With regards to our fund investment strategy, our vision is to collaborate closely with our portfolio funds, offering them access to our broad network and experience, as well as to co-invest alongside them into innovative blockchain companies and crypto assets."
Cryptology is one of the few stock-market listed investment companies exclusively focusing on crypto and blockchain related businesses, trading on multiple German exchanges under the ticker symbol CAP:GR and ISIN MT0001770107.
Cryptology offers retail and institutional investors unparalleled and easy access, via its daily liquid shares, to an exclusive asset class that is otherwise reserved for a small group of investors, given that most companies and funds in the crypto sector are still private. For example, Cryptology offers indirect participation in iconic crypto giant Block.one, the publishers of EOSIO, and their newly announced exchange, BULLISH.
Cryptology's fund investment strategy will strengthen its position as the leading access stock to a global, diversified crypto portfolio.
About Cryptology Asset Group p.l.c.
Cryptology is a leading European investment company for crypto assets and blockchain-related business models. Founded by Christian Angermayer's family office, Apeiron Investment Group and crypto-legend Mike Novogratz, Cryptology is the largest publicly traded holding company for blockchain- and crypto-based business models in Europe. Noteworthy portfolio companies include crypto-giant and EOSIO software publisher Block.one, leading HPC provider Northern Data, commission-free online neobroker nextmarkets, and crypto asset management group Iconic Funds.
| Language: | English | |
| Company: | Cryptology Asset Group PLC | |
| Beatrice 66 & 67, Amery Street | ||
| SLM 1707 Sliema | ||
| Malta | ||
| E-mail: | info@cryptology-ag.com | |
| Internet: | cryptology-ag.com | |
| ISIN: | MT0001770107 | |
| WKN: | A2JDEW | |
| Listed: | Regulated Unofficial Market in Dusseldorf | |
| EQS News ID: | 1203868 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005409/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference15.1.2026 01:40:00 CET | Press release
Samsung Bioepis plans to secure 20 biosimilars in its products and pipeline by 2030The new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki, vedolizumab, and ocrelizumab, in addition to pembrolizumab currently in Phase 1 and 3 clinical studiesHaving secured investigational new drug application (IND) clearance from the U.S. Food and Drug Administration (FDA), SBE303, Samsung Bioepis’ novel antibody-drug conjugate (ADC) engineered to target Nectin-4, will enter into the Phase 1 first-in-human clinical trial this yearSamsung Bioepis plans to add one novel therapeutic candidate in clinical study every year Samsung Epis Holdings (KRX: 0126Z0) today shared corporate progress and updates at the 44th J.P. Morgan Healthcare Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114206458/en/ Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings "2026 is a mon
Most Delivered Light-Entry Jet Cessna Citation M2 Gen2 With Garmin Autothrottles Enters Into Service, Bringing Greater Control and Precision to Pilots14.1.2026 20:30:00 CET | Press release
The Cessna Citation M2 Gen2 with Garmin Autothrottles recently entered into service. Certified by the Federal Aviation Administration in October 2025, the integration of Garmin’s Autothrottle system in the Citation M2 Gen2 further supports the most delivered light-entry jet’s capabilities by bringing greater control and precision to pilots. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114646844/en/ Most delivered light-entry jet Cessna Citation M2 Gen2 with Garmin Autothrottles enters into service, bringing greater control and precision to pilots (Photo Credit: Textron Aviation). The Cessna Citation M2 Gen2 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “We continue to invest in our products to provide customers with the best aviation experience in the world," said Lannie O’Bannion, senior vice president, Sales & Marketing. “The M2 Gen2 leads its segment as the most delivered
TwentyTwo Real Estate and Farallon Capital Complete €761 Million Investment in Isemia, a €1.2bn Healthcare Real Estate Company Created With emeis14.1.2026 18:30:00 CET | Press release
TwentyTwo Real Estate, an independent European real estate investment and management firm, announces the completion, alongside Farallon Capital, of a €761 million investment that led to the creation of Isemia (www.isemiabyemeis.com), a leading healthcare real estate company holding a €1.2 billion portfolio of assets operated by emeis. The transaction represents a significant milestone in TwentyTwo Real Estate’s long-term investment strategy focused on healthcare and operational living real estate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114262830/en/ Fachklinik Schömberg Isemia comprises 68 high-quality assets across France, Germany and Spain, with a balanced mix of nursing homes (48%) and clinics (52%). The portfolio benefits from strong fundamentals and resilient operating performance. All properties will continue to be operated by emeis under long-term lease agreements, ensuring continuity of care for residents
AI’s Water Demand to Surge Nearly 130% by 2050 – New Research Shows How to Build a Water-Secure AI Economy14.1.2026 16:00:00 CET | Press release
Analysis finds AI could add 30 trillion liters of annual water demand, but targeted reuse and digital infrastructure investments can substantially offset demand and protect communities The rapid global expansion of artificial intelligence is set to drive a 129% increase in water demand across the AI value chain by 2050, according to new research by Xylem (NYSE: XYL) and Global Water Intelligence (GWI). Watering the New Economy: Managing the Impacts of the AI Revolution provides the most comprehensive assessment to date of how AI is reshaping global water use. It also highlights practical ways to meet that demand while strengthening water security for communities. Spending on AI is forecast to approach $2 trillion in 2026,1 accelerating infrastructure build-out worldwide. By the middle of the century, this expansion is projected to add 30 trillion liters of water demand, annually, fueled by a surge in power generation (~54% of the increase), semiconductor fabrication (~42%), and data ce
ACCELQ Crowned Leader and Customer Favorite in The Forrester Wave™ for Autonomous Testing Platforms14.1.2026 16:00:00 CET | Press release
Agentic Test Automation Pioneer Caps Record-Breaking Year of Growth and "AI-Based Engineering Solution of the Year" Honors Forrester has named ACCELQ a Leader in The Forrester Wave™: Autonomous Testing Platforms, Q4 2025. This marks the third consecutive Wave in which ACCELQ has been recognized as a Leader. Notably, this evaluation placed strong emphasis on generative AI innovation and real-world customer adoption. ACCELQ received the highest scores for both capabilities and vision and was the only platform to be recognized as a Customer Favorite, earning a "double halo" for exceptional customer endorsement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113112861/en/ ACCELQ recognized as a Leader and Customer Favorite in The Forrester Wave™️: Autonomous Testing Platforms, Q4 2025, validating its agentic, GenAI-embedded testing vision. According to the Forrester report, ACCELQ received the highest score among all evaluate
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom